Smoke Inhalation Injury in Patients Admitted to Intensive Care (fumeintox)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03834246|
Recruitment Status : Recruiting
First Posted : February 7, 2019
Last Update Posted : February 7, 2019
Many Studies have shown that the smoke-inhalation injury is responsible for a high mortality mainly related to the systemic effects of carbon monoxide and cyanide. Respiratory lesions induced by smoke inhalation, is one of predictive factors of mortality.
The aim of the study is to identify the clinical and epidemiological characteristics of smoke-inhalation injury and to identify prognostic factors among these patients .
|Condition or disease|
|Smoke Inhalation Injury Morality|
The study is a monocentric, retrospective, descriptive and analytical study , betwen december 1997 and september 2018 in intensive care unit of university of hospital.
All patients aged over 18 year and who had received a diagnosis of smoke- inhalation injury and were admitted to the ICU of Medical University Hospital , a referral center in Paris providing HBO therapy , were potentially eligible for inclusion in this investigation.
Criteria used for recommending HBO therapy to a patient with transient or prolonged unconsciousness, abnormal neurologic findings on physical examination.
Data were analyzed to identify independent factors that may influence mortality.
|Study Type :||Observational|
|Estimated Enrollment :||700 participants|
|Official Title:||Prognostic Factors for Smoke Inhalation Injury in Patients Admitted to Intensive Care|
|Actual Study Start Date :||October 16, 2018|
|Estimated Primary Completion Date :||December 31, 2019|
|Estimated Study Completion Date :||May 31, 2020|
- mortality rate [ Time Frame: 20 years ]survival study for the search of prognostic factors
- epidemiologic characteritics [ Time Frame: 20 years ]description of quantitative and qualitative data
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03834246
|Contact: Rania BOUNAB, Dr||+33 (1) 74 10 firstname.lastname@example.org|
|Contact: Fatima IZEDAREN, CRA||+33 (1) 47 10 44 email@example.com|
|Garches, France, 92380|
|Contact: Rania BOUNAB 0698258796 firstname.lastname@example.org|
|Contact: rania Bounab 0147107778 email@example.com|
|Principal Investigator:||Rania BOUNAB, dr||Raymond Poincaré Hospital|